Tag: director

New York, N.Y., June 16, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Matthew Barry has joined the Company as its Director of Investor Relations.

Strategic federal initiative includes appointment of Jason Chasse, a US Federal and Military sales veteran with over 30 years of experience, as Director of Federal Sales.

Midland, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE: NGS), a leading provider of natural gas compression equipment, technology, and services to the energy industry, today announced that Stephen C. Taylor has transitioned from Chairman of the Board to the role of Chairman Emeritus, effective immediately. Concurrently, the Company’s Board of Directors has appointed Donald J. Tringali as Chairman. Mr. Taylor continues his role as a director on the Company’s Board.

Ningbo, China, June 16, 2025 (GLOBE NEWSWIRE) -- Skycorp Solar Group Limited (the “Company”) (NASDAQ: PN), a solar PV product provider engaged in the manufacture and sale of solar cables and solar connectors, highlighted its latest innovations at the 18th SNEC International Photovoltaic Power Generation and Smart Energy Conference & Exhibition. From June 11-13, 2025, its subsidiary, Ningbo Pntech New Energy Co., Ltd. (“PNTECH”), introduced advanced photovoltaic connection solutions, drawing substantial industry attention and reinforcing its position in renewable energy cable development.

MALVERN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory trial of OCU410ST, a modifier gene therapy candidate being developed for all Stargardt disease (ABCA4-associated retinopathies). The FDA previously granted Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.